You are viewing: North America Cancer Biomarkers Market analysis
Part of: Cancer Biomarkers Market (Global)

The North America Cancer Biomarkers Market was valued at $8598.8 Million in 2026 and projected to reach to $16517.1 Million by 2031, representing a compound annual growth rate of 11.5%. North America's cancer biomarkers market is poised for sustained expansion through 2031, driven by increasing prevalence of cancer diagnoses, growing adoption of liquid biopsy technologies, and rising demand for companion diagnostics.

North America Cancer Biomarkers Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

North America Cancer Biomarkers Market Trends and Insights

  • This 11.5% compound annual growth rate reflects North America's leadership in precision oncology, advanced diagnostic infrastructure, and substantial investment in cancer research and development.
  • North America benefits from high healthcare expenditure, widespread adoption of molecular testing, and strong regulatory frameworks that accelerate biomarker-driven treatment innovation. The North America market is driven by increasing prevalence of cancer diagnoses, growing demand for personalized medicine, and expanding reimbursement coverage for biomarker testing across the region.
  • North America's sophisticated healthcare systems and early adoption of next-generation sequencing technologies position the region as a critical hub for cancer biomarker commercialization.
  • Between 2026 and 2031, North America is expected to maintain its competitive advantage through continued clinical validation, integration of artificial intelligence in biomarker discovery, and strategic partnerships between diagnostic companies and oncology centers..

Key Market Statistics

  • CAGR (2026-2031) 11.5% CAGR
  • Market Size, 2026 ~USD 8598.8 Million
  • Forecast, 2031 ~USD 16517.1 Million
  • Geography North America

North America Cancer Biomarkers Market Overview

Market Leadership Position :

North America commands the largest share of the global cancer biomarkers market, driven by advanced healthcare infrastructure, high adoption of precision oncology, and substantial R&D investments from leading pharmaceutical and diagnostic companies.

Strong CAGR Trajectory :

With an 11.5% CAGR from 2026 to 2031, North America's market growth nearly doubles the global average, reflecting accelerating demand for personalized cancer diagnostics and targeted therapies across the US and Canada.

US Market Dominance :

The United States represents $15,157.3 million of the North American market, accounting for approximately 88% of regional value, supported by robust healthcare spending, FDA approvals, and extensive clinical trial infrastructure.

Regulatory and Innovation Ecosystem :

North America benefits from streamlined FDA approval pathways, significant venture capital funding, and collaboration between academic institutions and biotech firms, accelerating biomarker discovery and commercialization.

North America Cancer Biomarkers Market Dynamics

  • Healthcare providers across the US and Canada are increasingly integrating biomarker testing into standard oncology protocols, improving patient stratification and treatment outcomes. The region's competitive advantage stems from robust reimbursement policies, strong intellectual property protections, and continuous innovation in genomic sequencing and molecular diagnostics.
  • Strategic partnerships between diagnostic companies, pharmaceutical manufacturers, and healthcare systems will further accelerate market penetration, positioning North America as the global leader in precision oncology through 2031..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    In Vitro Diagnostics

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Dna Microarrays
    • Assay Kits
    • Microarrays
    Top Companies
    • ROCHE HOLDINGS AG
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Abbott Laboratories
    • Biomerieux s.a.

      Key Takeaways

      • North America's cancer biomarkers market will nearly double from $8.6B (2026) to $16.5B (2031), growing at 11.5% CAGR.
      • North America leads global adoption of precision oncology and next-generation sequencing technologies for cancer diagnosis and treatment selection.
      • Expanding reimbursement policies and high healthcare spending in North America drive widespread biomarker testing integration across oncology practices.
      • North America's advanced regulatory environment and strong R&D infrastructure position the region as the primary driver of biomarker innovation through 2031.

      Cancer Biomarkers Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment LUNG CANCER (Cancer Type)
      Forecast Period 2026–2031
      Growth Rate CAGR of 11.6% from 2026 to 2031
      Largest Segment OMICS TECHNOLOGIES (Profiling Technology)
      Market Size Base Year (Billions) ~USD 28.2 (2026)
      Revenue Forecast (Billions) ~USD 48.82 (2031)
      Segments Covered Profiling Technology, Type, Cancer Type, Products

      North America Cancer Biomarkers Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Profiling Technology

      • Imaging Technologies
      • Omics Technologies

      By Type

      • 2D Gel Electrophoresis
      • Antibodies
      • Biopsy Instruments
      • Computed Tomography (Ct)
      • Genomics
      • Imaging Instruments
      • Immunoassay
      • In-Situ Hybridization (Ish)
      • Kits And Reagents
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mass Spectrometry
      • Next Generation Sequencing
      • Other Omics Technologies
      • Other Proteomics Technologies
      • Pathology-Based Instrument
      • Polymerase Chain Reaction
      • Positron Emission Tomography (Pet)
      • Probes
      • Protein Microarray
      • Proteomics
      • Ultrasound Imaging

      By Cancer Type

      • Bladder Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Kidney Cancer
      • Leukemia
      • Lung Cancer
      • Melanoma
      • Non-Hodgkin'S Lymphoma
      • Other Cancer Types
      • Prostate Cancer
      • Thyroid Cancer

      By Products

      • Bioinformatics Software
      • Consumables
      • Instruments

      Target Audience

      • Diagnostic & Biotech Companies : In vitro diagnostics manufacturers and biotech firms need North America-specific market data to guide product development, clinical validation strategies, and commercialization timelines in the world's largest precision oncology market.
      • Pharmaceutical Manufacturers : Drug developers require detailed insights on companion diagnostic adoption, biomarker-driven patient stratification, and reimbursement landscapes across US and Canadian markets to optimize clinical trial design and market access.
      • Healthcare Providers & Hospitals : Cancer centers and hospital networks need market intelligence on emerging biomarker technologies, cost-effectiveness data, and adoption trends to inform procurement decisions and clinical protocol updates.
      • Investment & Private Equity Firms : Investors evaluating oncology diagnostics and precision medicine companies require North America market sizing, growth projections, and competitive dynamics to assess portfolio opportunities and valuation benchmarks.
      • Healthcare Policy & Regulatory Bodies : Government agencies and health authorities need comprehensive market data on biomarker adoption, healthcare spending trends, and innovation patterns to inform reimbursement policies and regulatory frameworks.

      Key Companies in the North America Cancer Biomarkers Market

      CompanyHQOwnershipStrongest segments
      NANOSTRING TECHNOLOGIES, INCUnited States
      CELL SIGNALING TECHNOLOGY, INC.United States
      TRANSGENOMIC, INC.United States
      SANOFISpain
      SIEMENS HEALTHINEERS AGGermanyPublic CompanyImaging-based biomarker systems and software,In-vitro diagnostics instruments and consumables,Varian oncology platforms and services,
      BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyInstruments (flow cytometers, analyzers, automation),Consumables & reagents (antibodies, kits, collection products, media),
      MYRIAD GENETICSUnited StatesPublic CompanyHereditary cancer and germline oncology tests (e.g., MyRisk, BRACAnalysis CDx),Tumor-based prognostic and companion diagnostics (MyChoice CDx, Prolaris, EndoPredict, Precise Tumor),Other oncology-adjacent genomics and lab services within cancer workflows,
      SYSMEX CORPORATIONJapanPublic CompanyInstruments (hematology, coagulation, cell analysis platforms),Consumables (reagents, calibrators, controls, software-linked services),
      HOLOGIC, INC.United StatesPrivate CompanyBreast cancer imaging systems and software,Biopsy guidance systems and markers,Cytology and related consumables (ThinPrep),

      NANOSTRING TECHNOLOGIES, INC

      NanoString Technologies develops and commercializes molecular analysis platforms for gene expression profiling and genomic research.

      CELL SIGNALING TECHNOLOGY, INC.

      Cell Signaling Technology Inc. produces research antibodies, proteins, and assay kits for cell biology and life sciences research.

      TRANSGENOMIC, INC.

      Transgenomic Inc. provides genetic testing and molecular diagnostics solutions for disease detection and management.

      SANOFI

      Sanofi is a multinational pharmaceutical company developing and marketing medicines, vaccines, and diagnostic products.

      SIEMENS HEALTHINEERS AG

      Siemens Healthineers AG is a global medical technology company providing diagnostic imaging, laboratory diagnostics, and healthcare IT solutions.

      BECTON, DICKINSON AND COMPANY

      Becton, Dickinson and Company manufactures and distributes medical devices, laboratory equipment, and diagnostic systems.

      MYRIAD GENETICS

      Myriad Genetics is a molecular diagnostics company providing genetic testing and precision medicine solutions for cancer and other diseases.

      SYSMEX CORPORATION

      Sysmex Corporation manufactures and sells hematology, hemostasis, and clinical chemistry diagnostic systems and reagents.

      HOLOGIC, INC.

      Hologic Inc. develops and markets diagnostic and medical imaging systems, particularly for women's health and cancer detection.

      North America vs. other regions

      HowNorth America compares to the other 3 regional blocs covered in this market.

      Europe
      ~USD 10349.2 Million · 12% wtd CAGR ·
      Asia Pacific
      ~USD 10318.4 Million · 14.4% wtd CAGR ·
      Latin America
      ~USD 2334.9 Million · 10.5% wtd CAGR ·
      Middle East & Africa
      ~USD 1366.4 Million · 9.9% wtd CAGR ·

      Countries within North America - compare and drill down

      Country2025 size (native)
      USUSD 15157.3 Million
      CanadaUSD 1777 Million

      Country market size visualization

      US
      USD 15157.3 Million
      Canada
      USD 1777 Million

      Reasons to Buy this Report

      • Market Size & Growth Validation : Access precise market valuations for North America ($8.6B in 2026, $16.5B in 2031) with country-level breakdowns for US and Canada, enabling accurate revenue forecasting and investment planning.
      • Competitive Landscape Intelligence : Understand North America's dominant market position with 11.5% CAGR, identify key players driving precision oncology adoption, and benchmark against global competitors operating in the region.
      • Regulatory & Reimbursement Insights : Gain clarity on FDA approval trends, insurance coverage policies, and healthcare spending patterns specific to US and Canadian markets that influence biomarker adoption and commercialization strategies.
      • Strategic Market Entry Planning : Leverage North America-specific data on healthcare infrastructure, clinical adoption rates, and technology preferences to develop targeted go-to-market strategies for diagnostic and pharmaceutical companies.
      • Investment Decision Support : Make informed capital allocation decisions with detailed North American market projections, growth drivers, and emerging opportunities in liquid biopsy, genomic sequencing, and personalized medicine.

      Frequently asked questions

      What is the projected market size for cancer biomarkers in North America by 2031?

      North America's cancer biomarkers market is projected to reach $16,517.1 million by 2031, up from $8,598.8 million in 2026, representing an 11.5% CAGR.

      What factors are driving growth in North America's cancer biomarkers market?

      North America's market growth is driven by increasing cancer prevalence, rising demand for personalized medicine, expanding reimbursement coverage, and widespread adoption of molecular testing technologies.

      How does North America's cancer biomarkers market compare to global trends?

      North America's 11.5% CAGR closely aligns with the global 11.6% CAGR, reflecting the region's significant contribution to and leadership in the worldwide cancer biomarkers market.

      Which technologies are most prevalent in North America's cancer biomarkers market?

      North America leads in adoption of next-generation sequencing (NGS), liquid biopsy, immunohistochemistry (IHC), and AI-integrated diagnostic platforms for cancer biomarker detection.

      What role does reimbursement play in North America's cancer biomarkers market expansion?

      Expanding insurance coverage and reimbursement policies in North America significantly accelerate biomarker testing adoption, enabling broader patient access and driving market growth through 2031.

      RESEARCH METHODOLOGY

      The objective of the study is to analyze key market dynamics, including drivers, opportunities, restraints, challenges, and key players' strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, the competitive landscape of the cancer biomarkers market will be analyzed, and market players will be evaluated on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.
      The four steps involved in estimating the market size are

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess prospects.

      The following is a breakdown of the primary respondents

      Cancer Biomarkers Market Size, and Share

      Note 1: Others include sales, marketing, and product managers.
      Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

      COMPANY NAME

      DESIGNATION

      Thermo Fisher (US)

      Sales Manager

      F. Hoffmann-La Roche AG (Switzerland)

      Product Manager

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total market size of cancer biomarkers. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry have been identified through extensive secondary research
      • The revenues generated by leading players operating in the cancer biomarkers market have been determined through primary and secondary research
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

      Cancer Biomarkers Market : Top-Down and Bottom-Up Approach

      Cancer Biomarkers Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the overall market size using the process described above, the total market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Cancer biomarkers are biological molecules produced by the body or a tumor in a person with cancer. Cancer biomarker testing helps differentiate alterations in the tumor. Biomarkers may be produced by the cancer tissue itself or by other cells in the body in response to cancer. It can also be found in the blood, stool, urine, tumor tissue, or other tissues or bodily fluids. Biomarkers can be DNA, RNA, proteins, or metabolomic profiles specific to the tumor. They enhance cancer detection and facilitate high-speed, noninvasive diagnosis using profiling technologies such as omics, imaging, immunoassays, and cytogenetics.

      Key Stakeholders

      • Product Manufacturers, Distributors, and Suppliers
      • Diagnostic Laboratories
      • Research Laboratories and CROs
      • Ambulatory Testing Centers
      • Contract Testing Laboratories
      • Academic Universities and Medical Research Centers
      • Research and Development (R&D) Centers

      Report Objectives

      • To define, segment, and forecast the cancer biomarkers market by profiling technology, cancer type, product, application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to six regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries
      • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To benchmark players within the market using the proprietary company evaluation matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
      • To study the impact of AI on the market, along with the macroeconomic outlook for each region

      Available customizations:

      MarketsandMarkets offers the following customizations for this market report.

      Product Analysis

      • Product matrix, which provides a detailed comparison of the product portfolio of each company in the cancer biomarkers market

      Country Information

      • Additional country-level analysis of the cancer biomarkers market

      Company Profiles

      • Additional five company profiles of players operating in the cancer biomarkers market.

      Get the Full Cancer Biomarkers Market Report

      Full forecast, segment splits, and company analysis for all Cancer Biomarkers Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status